EA200702256A1 - Микросферический васкулярный эмбол на основе альгината натрия,содержащий гинекологическое лекарственное средство, и его получение - Google Patents

Микросферический васкулярный эмбол на основе альгината натрия,содержащий гинекологическое лекарственное средство, и его получение

Info

Publication number
EA200702256A1
EA200702256A1 EA200702256A EA200702256A EA200702256A1 EA 200702256 A1 EA200702256 A1 EA 200702256A1 EA 200702256 A EA200702256 A EA 200702256A EA 200702256 A EA200702256 A EA 200702256A EA 200702256 A1 EA200702256 A1 EA 200702256A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sodium alginate
solution
vascular
emboles
microspheric
Prior art date
Application number
EA200702256A
Other languages
English (en)
Other versions
EA013680B1 (ru
Inventor
Цунцзянь Сюй
Синьцзянь Ли
Хун Хун
Гэ Лу
Original Assignee
Бейцзин Шенияо Сайнс Энд Текнолоджи Девелопмент Ко., Лтд.
Фудан Юнивесити Матенити Хоспитал
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бейцзин Шенияо Сайнс Энд Текнолоджи Девелопмент Ко., Лтд., Фудан Юнивесити Матенити Хоспитал filed Critical Бейцзин Шенияо Сайнс Энд Текнолоджи Девелопмент Ко., Лтд.
Publication of EA200702256A1 publication Critical patent/EA200702256A1/ru
Publication of EA013680B1 publication Critical patent/EA013680B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к разновидности микросферического васкулярного эмбола на основе альгината натрия, содержащего гинекологическое лекарственное средство, и к его получению. Его получение состоит из следующих стадий: приготовления раствора гинекологического лекарственного средства, альгината натрия и катионов двухвалентных металлов, например, BaCl, MgClили CaClи т.д. по порядку; смешивания раствора гинекологического лекарственного средства и раствора альгината натрия, и затем смешивания их с консервирующим раствором BaClили CaClи т.п. Затем получают микросферический васкулярный эмбол на основе альгината натрия, содержащий гинекологическое лекарственное средство. Материалы носителя васкулярного эмбола согласно изобретению являются природными экстрактами, обладают хорошей биологической совместимостью и являются биоразлагаемыми; побочный эффект фармацевтических средств, доставляемых ими, минимален, и они особенно подходят для болезней миометрия и гистеромиомы.
EA200702256A 2005-04-15 2005-04-15 Микросферический васкулярный эмбол на основе альгината натрия, содержащий гинекологическое лекарственное средство, и его получение EA013680B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2005/000506 WO2006108324A1 (fr) 2005-04-15 2005-04-15 Suppositoire vasculaire microsphérique contenant des composés pharmaceutiques gynécologiques d’alginate de sodium et sa méthode de préparation

Publications (2)

Publication Number Publication Date
EA200702256A1 true EA200702256A1 (ru) 2008-04-28
EA013680B1 EA013680B1 (ru) 2010-06-30

Family

ID=37086598

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702256A EA013680B1 (ru) 2005-04-15 2005-04-15 Микросферический васкулярный эмбол на основе альгината натрия, содержащий гинекологическое лекарственное средство, и его получение

Country Status (7)

Country Link
US (1) US20090028918A1 (ru)
EP (1) EP1870089A4 (ru)
JP (1) JP4937999B2 (ru)
KR (1) KR101163735B1 (ru)
CA (1) CA2602281C (ru)
EA (1) EA013680B1 (ru)
WO (1) WO2006108324A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101536986B (zh) * 2009-04-16 2011-05-04 北京圣医耀科技发展有限责任公司 含索拉非尼的海藻酸钠靶向缓释微球血管栓塞剂及其制备和应用
CN102429862B (zh) 2011-11-29 2013-05-01 江苏德达医药科技有限公司 一种聚维酮碘眼用缓释滴眼液
CN105362960A (zh) * 2015-12-18 2016-03-02 夏修菲 一种用于治疗子宫肌瘤的中药丸剂及制备方法
KR102288833B1 (ko) * 2019-09-11 2021-08-13 주식회사 메피온 자가 팽창형 색전물질의 제조 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06329542A (ja) * 1993-05-21 1994-11-29 Kibun Food Chemifa Co Ltd 不溶性アルギン酸塩粒子を含む局所血管止血用組成物および動脈化学塞栓用組成物
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
JPH09165328A (ja) * 1995-12-15 1997-06-24 Noboru Harada 小球体及びそれを含有する医薬用組成物
WO2001066016A1 (en) * 2000-03-06 2001-09-13 Scimed Life Systems, Inc. Embolic agents visible under ultrasound
CN1106845C (zh) * 2000-08-17 2003-04-30 洪宏 海藻酸钠固态微球血管栓塞剂的生产工艺
WO2002049501A2 (en) * 2000-12-18 2002-06-27 Board Of Regents, University Of Texas System Local regional chemotherapy and radiotherapy using in situ hydrogel
US6749845B2 (en) * 2001-02-15 2004-06-15 Aeropharm Technology, Inc. Modulated release particles for lung delivery
US7462366B2 (en) * 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US20040076582A1 (en) * 2002-08-30 2004-04-22 Dimatteo Kristian Agent delivery particle
CN1476897A (zh) * 2002-08-21 2004-02-25 中国科学院大连化学物理研究所 一种小粒径的蛋白质药物微球载体制备技术
WO2005041884A2 (en) * 2003-10-31 2005-05-12 Engineered Release Systems, Inc Polymer-based microstructures
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇－海藻酸钠微球血管栓塞剂及其制备
US20080160062A1 (en) * 2006-12-29 2008-07-03 Boston Scientific Scimed, Inc. Medical devices based on modified polyols

Also Published As

Publication number Publication date
EP1870089A4 (en) 2012-10-03
KR101163735B1 (ko) 2012-07-09
CA2602281A1 (en) 2006-10-19
CA2602281C (en) 2011-06-21
EA013680B1 (ru) 2010-06-30
KR20080009703A (ko) 2008-01-29
JP2008535870A (ja) 2008-09-04
EP1870089A1 (en) 2007-12-26
JP4937999B2 (ja) 2012-05-23
US20090028918A1 (en) 2009-01-29
WO2006108324A1 (fr) 2006-10-19

Similar Documents

Publication Publication Date Title
EA200800064A1 (ru) Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
EA200702320A1 (ru) Соединения trpv1 агониста и способы их получения и применения
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
WO2007062078A3 (en) Thrombopoietin activity modulating compounds and methods
WO2007024949A3 (en) Alpha2c adrenoreceptor agonists
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
ITPD20050242A1 (it) Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
RU2008111148A (ru) Применение комплексных соединений железа (iii) для производства лекарственного средства для перорального лечения железодефицитных состояний у больных, страдающих хроническими воспалительными заболеваниями кишечника
MY139086A (en) Use of debranched starch in extrusion-spheronization pharmaceutical pellets
EA200702256A1 (ru) Микросферический васкулярный эмбол на основе альгината натрия,содержащий гинекологическое лекарственное средство, и его получение
WO2008087366A3 (fr) Derives de 3-phenyl-1-(phenylthienyl)propan-1-one et de 3-phenyl-1-(phenylfuranyl)propan-1-one substitues, preparation et utilisation
GB2443793B (en) Product, method of manufacture and use
WO2011034916A3 (en) Bone substitute compositions, methods of preparation and clinical applications
DE602007014206D1 (de) Neuartige serotonin-wiederaufnahmehemmer als arzneimittel mit peripheriesystem-beschränkter aktivität
RU2006131758A (ru) Композиция для предупреждения простуды
TW200740424A (en) Taste masking dosage form
MX357919B (es) Composición farmacéutica para el tratamiento de la hipercolesterolemia.
TR201906742T4 (tr) Tıbbi bir ürün ve tedavi.
DE602006015968D1 (de) Zubereitungen von pro-insulin-c-peptid mit verzögerter freisetzung
UA92604C2 (ru) Композиция стансопорфина с физиологической осмотической концентрацией и ее применение
RU2005140097A (ru) Лекарственное средство для внутреннего применения, в частности, против раковых заболеваний
WO2003018568A3 (en) Ascorbic acid derivatives, methods of synthesis and pharmaceutical use thereof
Tan et al. Poly β-Cyclodextrin/Quaternary Ammoniated Chitosan Cryogel with a Porous Structure for Effective Hemostasis

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ MD TJ

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ KG TM RU